Bacitracin
Active ingredient · 4 therapeutic classes
Sold as BACITIN · BACIJECT · JAMPOLYCIN · DG Health Antibiotic · OZONOL ANTIBIOTICS PLUS
- Drug class
- Other Antibacterials
- Availability
- Over-the-counter
- Routes
- Topical, Intramuscular
- Markets covered
- 2
- Products on record
- 15
- FDA reports (12 mo)
- 122
Overview
Plain-language summary, compiled from the cited regulatory records
Bacitracin is an antibiotic used topically for first aid purposes [1]. It belongs to the drug class of other antibiotics for topical use [1]. Bacitracin is approved to help prevent infection in minor cuts, scrapes, and burns [1].
This active ingredient is available under various brand names, including DG Health Antibiotic and Triple Antibiotic and Pain Relief [1]. In the past 12 months, there have been 122 adverse event reports associated with products containing bacitracin [2]. The most frequently reported reactions include diarrhea, neurotoxicity, off-label use, weight increase, and the drug being ineffective [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 9 | October 30, 2025 |
| CA Canada | Health Canada | 6 | March 22, 2025 |
USUnited States· FDA
9 products
Uses
Uses first aid to help prevent infection in: • minor cuts • scrapes • burns
How to take
CACanada· Health Canada
6 products
Uses
BaciJect (Bacitracin for Injection USP) is indicated for: • The treatment of infants with pneumonia and empyema caused by staphylococci shown to be susceptible to the drug. • The treatment of secondarily infected wounds, ulcers, pyodermas and other superficial skin and eye infections when used as a topically applied solution.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of BaciJect and other antibacterial drugs, BaciJect should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.
When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Bacitracin is not indicated as an irrigation solution for intraoperative prophylaxis nor for pre-soaking of medical devices or implants prior to surgery. Anaphylactic reactions and nephrotoxicity can occur when bacitracin is used in this manner.
Drug interactions
Known interactions involving Bacitracin. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 00747e3a-389c-46… · revised November 6, 2024 [PDF]
- [2]Health Canada (DPD) · 02245571 · revised March 22, 2025
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.